Jumper JM, et al. - Researchers sought to ascertain the effectiveness, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice. Results demonstrated that <60% of patients achieved 20/40 or better best-corrected visual acuity (BCVA) after each anti-VEGF injection from the 1st to the 16th and ≤70% of patients achieved CRT ≤250 µm on time-domain optical coherence tomography (TD-OCT) or ≤300 µm on spectral-domain optical coherence tomography (SD-OCT). Blurry or cloudy vision was the most common treatment-related adverse event. As per data, a mean of 5 to 7 anti-VEGF injections was administered yearly, and in many patients the response to anti-VEGF therapy was suboptimal. They noted the Anti-VEGF therapy to be well tolerated.